The 23rd Orphan Drugs & Rare Diseases Global Congress 2025 Americas is dedicated to the critical issues shaping the future of Orphan Drugs in the Americas.
Topics
- How commercially viable Is It to Engage in the Development of Orphan Drugs?
- Trends and Deal Structures in Licensing Agreements
- Coming Together in Developing Orphan Drugs and Crossing Borders
- Finding innovative and alternative ways in funding the development of Orphan Drugs
- What is Orphan Drugs’ role in sustainability of the Pharmaceutical Industry?
- What Do Developers Look for When Looking for an Outsourcing Partner?
- Patient Access: How Can This Continue to Improve?
- How Can the Developer and the Patient Assist in the Evolution and Development of Orphan Drugs?
- What Do Insurance Companies Think About Orphan Drugs? Will They Make Modifications to Their Policies to Support Patients with Rare Diseases?
Who should Attend
Senior attendees with responsibilities in:
- Personalised Medicine
- Research and Development
- External R&D Innovation
- Regenerative Medicine
- Rare and Ultra-Rare Diseases
- Innovative Medicine
- Cell and Gene Therapy
- Therapeutic Are Lead
- Molecular Geneticist
- Translational Science
- Patient Advocacy Groups
- Program Management
- Public Affairs
- Patient Engagement
- Regulatory Affairs
- Medical Affairs
- Market Access
- Clinical Research Organizations
- Pricing and Reimbursement
- Managed and Early Access
- Commercial Development
- Health Economics Outcomes Research
- Product Specialist
- Investments and Funding
- Business Planning and Operations
- Global Strategic Services
- Academia
- Speciality Pharmacies
